Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Intellia Therapeutics Inc
NTLACurrent price
7.23 USD
+0.37 USD (+5.39%)
Last closed
6.54 USD
Company
www.intelliatx.com
ISIN
US45826J1051
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
748 427 904 USD
Yield for 12 month
-66.88 %
1Y
3Y
5Y
10Y
15Y
NTLA
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 40 Erie Street, Cambridge, MA, United States, 02139
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
43.69 USDP/E ratio
–Dividend Yield
–Current Year
+57 877 000 USD
Last Year
+36 275 000 USD
Current Quarter
+12 874 000 USD
Last Quarter
+9 111 000 USD
Current Year
+57 877 000 USD
Last Year
+27 299 000 USD
Current Quarter
+12 874 000 USD
Last Quarter
+9 111 000 USD
Key Figures NTLA
1 year
3 years
5 years
10 years
EBITDA
-523 977 984 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-26.80 %
PEG Ratio
-0.097
Return On Equity TTM
-54.01 %
Wall Street Target Price
43.69 USD
Revenue TTM
57 877 000 USD
Book Value
8.55 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-24.00 %
Dividend Yield
–
Gross Profit TTM
-408 433 984 USD
Earnings per share
-5.25 USD
Diluted Eps TTM
-5.25 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NTLA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History NTLA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation NTLA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
6.17
Price Sales TTM
12.93
Enterprise Value EBITDA
-5.51
Price Book MRQ
0.86
Financials NTLA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NTLA
For 52 weeks
5.90 USD
28.18 USD
50 Day MA
9.04 USD
Shares Short Prior Month
26 688 670
200 Day MA
15.74 USD
Short Ratio
7.91
Shares Short
26 937 869
Short Percent
29.57 %
BeatStart